Edwards Q3 Earnings & Revenues Surpass Estimates, Stock Climbs

Edwards Lifesciences reported Q3 2026 adjusted EPS of $0.80, up 19% year over year and 9.6% above consensus, while revenue rose 10.5% to $1.72 billion, beating estimates by 2.4%; shares gained nearly 2.2% in after-hours trading. TMTT sales surged 44% to $207 million, adjusted operating margin expanded 280 bps to 30.3%, and the company raised 2026 constant-currency sales growth guidance to approximately 11.5% and adjusted EPS guidance to $2.97-$3.05. It also repurchased approximately $700 million of shares in the first nine months of 2026.

Analysis

The key read-through is not the headline beat, but whether incremental TAVR access and TMTT adoption convert into durable procedure growth without diluting economics. TMTT’s fast growth is strategically meaningful, yet its smaller base makes it a weak near-term proxy for consolidated earnings: monitor absolute sales contribution, utilization and reimbursement rather than extrapolating the growth rate. In TAVR, reported share gains are described as modest; this supports the franchise but does not establish a decisive competitive break from Medtronic or other alternatives.

The margin story deserves a quality-of-growth discount until it is replicated. FX supplied half of the gross-margin expansion, while flat R&D dollars against higher sales lowered R&D intensity mechanically; neither alone demonstrates structural cost leverage. More importantly, Q4 EPS guidance is below the cited consensus despite the full-year outlook increase. That creates near-term estimate-risk if investors treat the annual raise as a clean earnings acceleration.

Over 1–3 months, watch Q4 conversion, procedure growth, and whether management can meet the implied earnings bar while funding launches. Over 6–18 months, broader reimbursement and earlier-intervention evidence could enlarge the addressable TAVR pool, but clinical adoption and payer implementation will lag announcements. Reversal signals: slowing procedure growth, TMTT adoption without improving contribution, renewed margin contraction excluding FX, or guidance falling below the current range. Consensus may overvalue TMTT’s headline growth while underweighting the Q4 EPS setup; the upside thesis is therefore conditional, not a chase.

Key Decisions for Investors

• Prefer EW on post-event weakness rather than adding into a gap: the structural demand case is intact, but the Q4 EPS guide creates a plausible near-term estimate reset. Reassess after Q4 results and procedure-volume disclosures.
• For a relative-value expression, modestly overweight EW against a diversified medtech exposure, sized as a catalyst trade rather than a long-term secular-growth allocation. Exit or cut if TAVR procedure growth decelerates or operating-margin gains reverse after adjusting for FX.
• Do not capitalize TMTT’s reported growth rate directly into a valuation premium yet. Track quarterly absolute sales, procedure adoption, reimbursement and launch-related costs; treat evidence of growth translating into sustained margin contribution as the confirmation trigger.
• Monitor the Q4 EPS gap versus consensus and the composition of gross-margin change. A miss accompanied by weaker underlying margins would falsify the near-term bullish setup; revenue delivery with stable ex-FX margins would support adding.